Human iPS Cell Line (Normal)

Description

Product Description

Induced Pluripotent Stem Cells (iPSCs) are a type of stem cells generated by reprogramming a variety of mature, specialized somatic cells into an embryonic-like pluripotent state. iPSCs exhibit large self-renewal capability and can differentiate into cells from all three germ layers ^{[1, 2]}. Due to their high differentiation potential, iPSC serves as a unique cell model for the regenerative medicine. In addition, iPSCs reprogrammed from rare disease carriers can be expanded and differentiated into specific cell types, allowing research with genetically pertinent disease-specific cell models for personalized treatment ^[3]. iPSCs, thus, provide a unique model for studying a variety of processes that occur in the early development and become a promising tool in cell therapy of human diseases ^[4].

iXCells Biotechnologies is proud to offer human iPSCs derived from normal and patient somatic cells (dermal fibroblasts or peripheral blood mononuclear cells) with different race, gender, and age options to choose from. The pertinent donor information is available on the CoA or upon request ([email protected]). These iPSCs are established from single clones and expanded in feeder-free conditions. iXCells’ iPSCs demonstrate hESC morphology, express pluripotency markers, have normal karyotype, and are integration free (Figure 1). The iPSCs have been extensively used in differentiation projects to generate various cell types, including neurons, astrocytes, microglia, skeletal muscles, and hepatocytes (Figure 2). They are negative for mycoplasma, bacteria, yeast, fungi,HIV-1, HBV and HCV. In addition, patient-derived iPS cell lines are also available as separate products. The currently available disease specific iPS cell lines are derived from patients with Type 2 Diabetes (T2D; Cat#30HU-005), Alzheimer’s Disease (AD; Cat#30HU-008, Cat#30HU-009), Amyotrophic Lateral Sclerosis (ALS; Cat#30HU-004). More disease-specific iPS lines are under development. We also provide custom iPSC generation and iPSC differentiation services to meet your needs.

Figure 1. iXCells human iPS Cell Lines are characterized by immunostaining targeting Oct4, Nanog, TRA-1-60, and TRA-1-81. Images are also stained with DAPI to show cell nuclei. Scale bar = 100μm.

Figure 2. iXCells human iPS Cell Lines demonstrate a high capacity for differentiation into various cell types, including Neurons, Skeletal Muscles, and Astrocytes. Scale bar = 100μm.

Product Details

Organism	Homo Sapiens, Human
Tissue Origin	Dermal fibroblast or peripheral blood mononuclear cells
Cell Type	iPSC
Disease	Normal
Package Size	0.5-1.0 x 106cells/vial
Growth Properties	Adherent
Product Format/Shipped	Cryopreserved
Storage	Liquid Nitrogen
Associated Media	Human iPSC Feeder-Free Growth Medium (Cat# MD-0019) Human iPSC Xeno-Free Growth Medium (Cat# MD-0074)

References

[1] Medvedev, S. P., Shevchenko, A. I., & Zakian, S. M. (2010). Induced Pluripotent Stem Cells: Problems and Advantages when Applying them in Regenerative Medicine. Acta naturae, 2(2), 18–28.

[2] Ghaedi, M., & Niklason, L. E. (2019). Human Pluripotent Stem Cells (iPSC) Generation, Culture, and Differentiation to Lung Progenitor Cells. Methods in molecular biology (Clifton, N.J.), 1576, 55–92.

[3] Okita, K., Matsumura, Y., Sato, Y., Okada, A., Morizane, A., Okamoto, S., Hong, H., Nakagawa, M., Tanabe, K., Tezuka, K., Shibata, T., Kunisada, T., Takahashi, M., Takahashi, J., Saji, H., & Yamanaka, S. (2011). A more efficient method to generate integration-free human iPS cells. Nature methods, 8(5), 409–412.

[4] Ebert, A. D., Liang, P., & Wu, J. C. (2012). Induced pluripotent stem cells as a disease modeling and drug screening platform. Journal of cardiovascular pharmacology, 60(4), 408–416.

Datasheet & Culture Protocol